دورية أكاديمية

Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series.

التفاصيل البيبلوغرافية
العنوان: Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series.
المؤلفون: Waheed, Sana, Attia, Doaa, Estrella, Michelle M., Zafar, Yousuf, Atta, Mohamed G., Lucas, Gregory M., Fine, Derek M.
المصدر: Clinical Kidney Journal; Aug2015, Vol. 8 Issue 4, p420-425, 6p
مصطلحات موضوعية: TENOFOVIR, HIV-positive persons, FANCONI syndrome, KIDNEY function tests, STANDARD deviations
مستخلص: Background: Tenofovir disoproxil fumarate (TDF) may cause acute kidney injury and proximal tubular dysfunction. However, no detailed studies document urinary phosphate wasting as a marker of TDF-induced tubulopathy. Methods: Records of HIV-infected patients with presumed TDF toxicity were reviewed. We describe the characteristics and clinical course of 15 patients who had documented elevated (>20%) fractional excretion of phosphate (FEphos). Results: Patientswere predominantly Caucasian and male (73 and 80%, respectively), with a mean age of 56 years (range 38-76). Of the 15 patients, 11 had a estimated glomerular filtration rate (eGFR) of >90 mL/min/1.732 at time of TDF initiation. The mean duration of TDF therapy prior to diagnosis of TDF toxicity was 64 months. Mean FEphos was 34% (range 20-62). The mean eGFR at TDF initiationwas 104 mL/min/1.73m² [standard deviation (SD) 17.0] with a gradual decline to 69 mL/min/1.73m² (SD 19.0) by the time of TDF discontinuation. Of 10 patients with repeated FEphos after TDF discontinuation, 9 had improvement of their FEphos. Of these individuals, 6 had normalization of their FEphos. Estimated GFR improved in 12 patients after discontinuation of TDF, though importantly, none returned to their baseline eGFR. Conclusions: Urinary phosphate wasting is a sensitive marker for TDF-induced proximal tubulopathy and is associated with unrecognized and permanent renal function decline. Tubular dysfunction can develop after years of TDF therapy in those with normal kidney function at the time of drug initiation. This suggests that continuing vigilance be maintained in all those on TDF. [ABSTRACT FROM AUTHOR]
Copyright of Clinical Kidney Journal is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:20488505
DOI:10.1093/ckj/sfv041